A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK3640254 in Healthy Participants

Trial Profile

A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK3640254 in Healthy Participants

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs GSK 3640254 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; First in man
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 31 Aug 2017 Planned End Date changed from 24 Jun 2018 to 19 Jul 2018.
    • 31 Aug 2017 Planned primary completion date changed from 24 Jun 2018 to 19 Jul 2018.
    • 31 Aug 2017 Planned initiation date changed from 5 Sep 2017 to 26 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top